<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348136</url>
  </required_header>
  <id_info>
    <org_study_id>JR-141-302</org_study_id>
    <nct_id>NCT04348136</nct_id>
  </id_info>
  <brief_title>An Extension Study of JR-141 in Patients With Mucopolysaccharidosis II</brief_title>
  <official_title>An Extension Study of JR-141-301 in Patients With Mucopolysaccharidosis II</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JCR Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JCR Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, single-group, designed to evaluate the long term efficacy and safety
      of study drug for the treatment of the MPS II.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>up to approximately 3 years</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>up to approximately 3 years</time_frame>
    <description>Antidrug antibodiesLaboratory tests (hematologic test, blood biochemical test, determination of iron-related levels and urine analysis)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>up to approximately 3 years</time_frame>
    <description>Vital signs (pulse rate, body temperature, and blood pressure,Blood pressures in mmHg,Heart rate in beats/minute,Respiratory rate in breaths/minute,Temperature in °C,Presence or absence of abnormalities for physical examination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>up to approximately 3 years</time_frame>
    <description>Presence or absence of abnormalities for 12-lead electrocardiogram</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>up to approximately 3 years</time_frame>
    <description>Antibody tests</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>up to approximately 3 years</time_frame>
    <description>• Routine laboratory tests in blood (hematology, liver function, renal function, iron-related levels) and urine (urinalysis)Infusion Associated Reaction (IAR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Serum Heparan Sulfate Levels.</measure>
    <time_frame>78, 104, 130 weeks,the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Serum Dermatan Sulfate Levels.</measure>
    <time_frame>78, 104, 130 weeks,the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Urinary Heparan Sulfate Levels.</measure>
    <time_frame>78, 104, 130 weeks,the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Urinary Dermatan Sulfate Levels.</measure>
    <time_frame>78, 104, 130 weeks,the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Liver Volumes.</measure>
    <time_frame>78, 104, 130 weeks,the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Spleen Volumes.</measure>
    <time_frame>78, 104, 130 weeks,the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Echocardigraphy</measure>
    <time_frame>78, 104, 130 weeks,the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in 6-minute Walk Test Distance.</measure>
    <time_frame>104 weeks, the end of the study*</time_frame>
    <description>Item 9 will be administrated only in patients judged by the investigator or subinvestigator to be possible to perform the 6-minutes walk test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Joint Range of Motion (goniometer)</measure>
    <time_frame>104, 130 weeks, the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Heparan Sulfate Levels in Cerebrospinal Fluid.</measure>
    <time_frame>104 weeks, the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Dermatan Sulfate Levels in Cerebrospinal Fluid.</measure>
    <time_frame>104 weeks, the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Neurocognitive Testing (Kyoto Scale of Psychological Development 2001)</measure>
    <time_frame>104 weeks, the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Adaptive Behavioral Testing ( Vineland Adaptive Behavior Scales Second Edition. )</measure>
    <time_frame>104 weeks, the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Cognitive Testing (Bayley Scales of Infant and Toddler Development, Third Edition. )</measure>
    <time_frame>104 weeks, the end of the study*</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From the first dose of the previous study (JR-141-301) in Cognitive Testing (Kaufman Assessment Battery for Children, Second Edition)</measure>
    <time_frame>104 weeks, the end of the study*</time_frame>
    <description>*Target patients: Patients who haven't conducted the test for more than 26 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Mucopolysaccharidosis II</condition>
  <arm_group>
    <arm_group_label>JR-141</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JR-141</intervention_name>
    <description>IV infusion, 2.0 mg/kg/week</description>
    <arm_group_label>JR-141</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who will have completed clinical trial JR-141-301 and judged by the
             investigator or subinvestigator to be able to participate in the study from safety
             aspects.

          2. Capable of providing written consent by himself, unless the patient is under the age
             of 20 years at the time of informed consent process, or it is not possible to obtain
             consent from the patient himself due to his intellectual disabilities associated with
             MPS II.

          3. In the case of a patient who is under the age of 20 years or from whom it is not
             possible to obtain consent due to his intellectual disabilities associated with MPS
             II, he may be included if written consent can be provided by legal representative;
             however written consent should be obtained from the patient himself too, wherever
             possible.

        Exclusion Criteria:

          1. Judged by the investigator or subinvestigator to be ineligible to participate in the
             study due to receive concomitant therapy which affectseffect the clinical evaluation.

          2. Judged by the investigator or subinvestigator to be ineligible to participate in the
             study due to a history of a serious drug allergy or sensitivity.

          3. Otherwise judged by the investigator or subinvestigator to be ineligible to
             participate in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fukui Clinical site</name>
      <address>
        <city>Fukui</city>
        <zip>910-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Clinical site 2</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuoka Clinical site</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gifu Clinical site</name>
      <address>
        <city>Gifu</city>
        <zip>501-1194</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hokkaido Clinical site</name>
      <address>
        <city>Hokkaido</city>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kananagawa Ckinical site</name>
      <address>
        <city>Kanagawa</city>
        <zip>232-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumamoto Clinical site</name>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Clinical site</name>
      <address>
        <city>Okayama</city>
        <zip>701-1192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama Clinical site 2</name>
      <address>
        <city>Okayama</city>
        <zip>710-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okinawa Clinical site</name>
      <address>
        <city>Okinawa</city>
        <zip>903-0215</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site 3</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site 2</name>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Clinical site</name>
      <address>
        <city>Osaka</city>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saitama Clinical site</name>
      <address>
        <city>Saitama</city>
        <zip>330-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Clinical site</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Clinical site 2</name>
      <address>
        <city>Shizuoka</city>
        <zip>426-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tochigi Clinical site</name>
      <address>
        <city>Tochigi</city>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Clinical site</name>
      <address>
        <city>Tokyo</city>
        <zip>157-8535</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tottori Clinical site</name>
      <address>
        <city>Tottori</city>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

